Zobrazeno 1 - 10 of 32 pro vyhledávání: '"Bienvenu Loembe"'
2
DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment
Autor: Michelle McMullen, Emma Dean, Bienvenu Loembe, Amit M. Oza, Katherine Karakasis, Graem Parr
Publikováno v: International Journal of Gynecological Cancer
BackgroundWith the success of poly(ADP-ribose) polymerase (PARP) inhibitor therapy in the first-line and second-line treatment settings, a new patient population is emerging with platinum-sensitive relapsed ovarian cancer, who have previously receive
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8092ed10fd5b94a2613e848955d3c54f
https://doi.org/10.1136/ijgc-2020-001694
Zobrazit plný text záznamu
3
Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer
Autor: Minsuk Kwon, Seung Tae Kim, Jung Yong Hong, Gahyun Kim, Simon Smith, Peter G. Mortimer, Bienvenu LoembE, Emma Dean, Won Ki Kang, Jeeyun Lee
Publikováno v: Journal of Clinical Oncology. 40:4045-4045
4045 Background: Alterations in DNA damage response (DDR) and repair are associated with genomic instability and increased somatic tumor mutational burden, and modulating DNA repair using specific inhibitors is a promising strategy to boost the effic
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7ae0bb5b3813ee6f6d1e2e6940d2e9fe
https://doi.org/10.1200/jco.2022.40.16_suppl.4045
Zobrazit plný text záznamu
4
A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3)
Autor: Pilar Garrido, Yvonne Summers, Ute von Wangenheim, Michael Flynn, Allan Hackshaw, Manuel Cobo, Siow Ming Lee, Anne-Marie C. Dingemans, Arsene Bienvenu Loembe, David Schnell, Rolf Kaiser, Martin Forster, Tommaso De Pas
Publikováno v: Lung Cancer, 120, 27-33. Elsevier Ireland Ltd
Background There are limited treatment options for squamous non-small cell lung cancer (sqNSCLC) and prognosis remains poor. The safety and pharmacokinetics (PK) of nintedanib, a triple angiokinase inhibitor, plus cisplatin/gemcitabine as first-line
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::204e811c903afe39963af83e951fdf83
https://doi.org/10.1016/j.lungcan.2018.03.007
Zobrazit plný text záznamu
5
mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib
Autor: Tim Meyer, Daniel H. Palmer, Julia Hocke, Ann-Lii Cheng, Chia Jui Yen, Arsene Bienvenu Loembe
Publikováno v: Liver International. 37:1047-1055
BACKGROUND & AIMS: Response Evaluation Criteria in Solid Tumors (RECIST) has been shown to be a poor surrogate for survival benefit with targeted therapy in advanced hepatocellular carcinoma (HCC). METHODS: We investigated whether response evaluated
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58e7316e505754bf0d623bae39deb1c8
https://doi.org/10.1111/liv.13359
Zobrazit plný text záznamu
6
Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment
Autor: Shuichi Mitsunaga, Taiga Otsuka, Rie Sugimoto, Arsene-Bienvenu Loembe, Kei Muro, Masafumi Ikeda, Yusuke Tadayasu, Kohei Inoue, Isao Saito, Takuji Okusaka, Hideki Ueno
Publikováno v: Cancer Science
This phase I, dose‐escalation study evaluated the safety, preliminary efficacy and pharmacokinetics of nintedanib, a triple angiokinase inhibitor, in Japanese patients with advanced hepatocellular carcinoma and mild/moderate liver impairment. Thirt
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a052d720809228c6216a50efb0c8b3f2
https://doi.org/10.1111/cas.13077
Zobrazit plný text záznamu
7
Phase II study of ceralasertib (AZD6738), in combination with durvalumab in patients with metastatic melanoma who have failed prior anti-PD-1 therapy
Autor: Jeeyun Lee, P Mortimer, Emma Dean, Minsuk Kwon, Claire Smith, Simon Smith, Bienvenu Loembe, Iwanka Kozarewa, Seung Tae Kim
Publikováno v: Journal of Clinical Oncology. 39:9514-9514
9514 Background: Alterations in DNA damage response (DDR) and repair are associated with genomic instability and increased somatic tumor mutational burden, and modulating DNA repair is a promising strategy to boost the efficacy of cancer immunotherap
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e41bdff4faa0210d286807a4c282ee5b
https://doi.org/10.1200/jco.2021.39.15_suppl.9514
Zobrazit plný text záznamu
8
Contextualizing a single-arm trial of ceralasertib (cer) plus paclitaxel with real-world data (RWD) in patients (pts) with advanced melanoma previously treated with anti-PD-(L)1(PDx) therapies
Autor: Simon Smith, Claire Smith, Jeeyun Lee, Sajan Khosla, Miao Jiang, Emma Dean, Bienvenu Loembe, Dan Jackson
Publikováno v: Journal of Clinical Oncology. 39:e21542-e21542
e21542 Background: Metastatic melanoma, especially in pts who do not respond to PDx therapy, is an area of high unmet need. Chemotherapy may be used but clinical efficacy is limited. A recent Phase I study (NCT02630199) showed that cer + paclitaxel h
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::873e3fb45685f2334c2887bfeed8b9bb
https://doi.org/10.1200/jco.2021.39.15_suppl.e21542
Zobrazit plný text záznamu
9
PLANETTE: A modular phase IIa multicenter open-label study evaluating the ATR inhibitor ceralasertib (AZD6738) in ATM mutant advanced solid tumors
Autor: Elkhan Sanay, Emma Dean, Natalia Lukashchuk, Andrew J. Pierce, Nisha Kurian, Graeme Parr, Bienvenu Loembe, Alan Lau, Wessel de Graaf, Rahul Aggarwal, Wassim Abida, Vidalba Rocher Ros
Publikováno v: Journal of Clinical Oncology. 39:TPS189-TPS189
TPS189 Background: Ataxia telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3-related (ATR) are kinases that orchestrate cellular responses to DNA damage. ATM is primarily activated by DNA double strand breaks, and ATR is recruited to reg
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::19676e50b595183f189f07cc39d1f0f0
https://doi.org/10.1200/jco.2021.39.6_suppl.tps189
Zobrazit plný text záznamu
10
Abstract 5427: Genomic prevalence analysis in TNBC patients in the Phase 2 VIOLETTE study
Autor: Natalia Lukashchuk, J. Carl Barrett, Andrew Tutt, Joshua Armenia, Hannah McGarvey, Zhongwu Lai, Andrew J. Pierce, Bienvenu Loembe, Emma Dean, Elizabeth A. Harrington, Sarah Edgington
Publikováno v: Cancer Research. 80:5427-5427
Introduction: Triple-negative breast cancer (TNBC) accounts for ~15-20% of all breast carcinomas. VIOLETTE is a global, multicentre, open-label, randomized phase 2b study (NCT03330847), recruiting patients with metastatic TNBC to 2 treatment arms: ol
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::83b08497099f8692080024fb525b1c98
https://doi.org/10.1158/1538-7445.am2020-5427
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje